Pancreatic Cancer Research

ResearcherCardiff UniversityActive in the last 2 years

Chris N Hurt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1206-8355; OpenAlex author ID A5051264415. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 10

  1. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/ra… Co-author DOI 10.1016/j.ejca.2024.114236↗
  2. Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1038/s41416-020-01120-z↗
  3. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-021-00192-1↗
  4. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for lo… Co-author DOI 10.1186/s12885-019-5307-z↗
  5. Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.clon.2018.02.067↗
  6. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pa… Co-author DOI 10.1038/bjc.2017.95↗
  7. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial. Co-author DOI 10.1016/j.radonc.2016.07.002↗
  8. Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.08.026↗
  9. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP tr… Co-author DOI 10.1016/j.radonc.2015.08.026↗
  10. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. First author DOI 10.1016/s1470-2045(13)70021-4↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Somnath Mukherjee · 10 shared papers, 2013–2024 · strength 0.79
  2. Tim Maughan · 6 shared papers, 2013–2024 · strength 0.49
  3. Eric E. O’Neill · 3 shared papers, 2019–2024 · strength 0.35
  4. M. Hawkins · 3 shared papers, 2018–2024 · strength 0.33
  5. Christopher Mark Jones · 2 shared papers, 2021–2024 · strength 0.27
  6. Ganesh Radhakrishna · 3 shared papers, 2013–2024 · strength 0.27
  7. D. Holyoake · 2 shared papers, 2018–2024 · strength 0.25
  8. Ross Allen Abrams · 5 shared papers, 2013–2017 · strength 0.24
  9. Pippa G. Corrie · 2 shared papers, 2019–2024 · strength 0.24
  10. Harpreet Singh Wasan · 2 shared papers, 2013–2024 · strength 0.19
  11. Thankamma Ajithkumar · 1 shared paper, 2024 · strength 0.16
  12. Frances W. Willenbrock · 1 shared paper, 2021 · strength 0.12
  13. Daniel Llwyd Hughes · 1 shared paper, 2021 · strength 0.12
  14. Emmanouil Fokas · 2 shared papers, 2015–2016 · strength 0.11
  15. Michelle Rodriques Goulart · 1 shared paper, 2021 · strength 0.11
  16. Jennifer Watt · 1 shared paper, 2021 · strength 0.11
  17. Christine Hughes · 1 shared paper, 2021 · strength 0.11
  18. Rita Teresa Lawlor · 1 shared paper, 2021 · strength 0.11
  19. Tatjana Crnogorac‐Jurcevic · 1 shared paper, 2021 · strength 0.11
  20. Hemant Mahendrakumar Kocher · 1 shared paper, 2021 · strength 0.11
  21. Aldo Scarpa · 1 shared paper, 2021 · strength 0.11
  22. Paola Allavena · 1 shared paper, 2021 · strength 0.11
  23. Roberto Salvia · 1 shared paper, 2021 · strength 0.11
  24. Mike Partridge · 1 shared paper, 2018 · strength 0.09
  25. Victoria Y. Strauss · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.